Case Report
Copyright ©2010 Baishideng. All rights reserved.
World J Hepatol. May 27, 2010; 2(5): 192-197
Published online May 27, 2010. doi: 10.4254/wjh.v2.i5.192
A successful treatment by hepatic arterial infusion therapy for advanced, unresectable biliary tract cancer
Masako Nishimura
Masako Nishimura, Department of Gastroenterology, Otsu Red Cross Shiga Hospital, 298 Wani- naka, Otsu, Shiga 520-0580, Japan
Author contributions: Nishimura M contributed solely to this paper.
Correspondence to: Masako Nishimura, MD, Department of Gastroenterology, Otsu Red Cross Shiga Hospital, 298 Wani- naka, Otsu, Shiga 520-0580, Japan. nishimu@hkg.odn.ne.jp
Telephone: +81-77-5948777 Fax: +81-77-5948778
Received: November 30, 2009
Revised: March 23, 2010
Accepted: March 30, 2010
Published online: May 27, 2010
Abstract

Biliary tract cancers (BTC) are relatively rare tumors, and the prognosis is extremely poor. There has been no standard chemotherapy for advanced BTC. However, recently, gemcitabine (GEM) have been used against BTC as the most active agent, and promising response rates and overall survival times with tolerable drug toxicities have been observed. In this article, two cases of advanced intrahepatic cholangiocarcinoma and unresectable metastatic gallbladder (GB) cancer are reported. They were treated with hepatic arterial infusion (HAI) chemotherapy using a combination of GEM and cisplatin, along with the systemic administration of GEM. As a consequence, multiple liver tumors, the GB cancer and metastatic lymph nodes regressed without severe drug toxicities, and favorable results (the overall survival times were 16 and 14 mo, respectively) were achieved. In conclusion, HAI therapy using GEM combined with cisplatin may be a useful and well-tolerated option for advanced BTC, especially in cases where multiple liver metastases are detected.

Keywords: Hepatic arterial infusion, Gemcitabine, Cisplatin, Intrahepatic cholangiocarcinoma, Gallbladder cancer